ArticleBMC pediatrics2025
Evaluation of commercial point-of-care glucometers for detection and monitoring of neonatal hypoglycemia in resource-constrained settings.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate identification and treatment of hypoglycemia or low blood glucose is important for neonates, especially premature, small for gestational age, and intra-uterine growth restricted (“small and sick”) newborns. Existing point-of-care (POC) adult glucometers, intended for home management of adults or children with diabetes, are widely available and less costly than machines designed and validated for neonates, but they must be validated at the lower glucose levels relevant for neonates and at appropriate hematocrit levels before being used for neonates.
methodsWe simulated neonatal blood by altering hematocrit (to 18%, 40%, and 55%) and glucose concentration (to 40 mg/dL and 150 mg/dL) of normal adult blood. We then used 11 POC glucometers to measure glucose levels in these samples and compared results to values measured with a clinical chemistry analyzer (YSI 2300).
resultsWe report mean percent bias, mean absolute relative difference, and standard deviation for each tested condition and glucometer. We ranked the tested glucometers based on a combination of accuracy and precision for measuring neonatal glucose levels and consumable cost. From best-performing to worst, they are Group 1: StatStrip and StatStrip Xpress 2; Group 2: AccuChek Guide, AccuChek GuideMe, AccuChek Instant, and AccuChek Performa; Group 3: AccuChek Active, GlucoNavii; Group 4: HemoCue RT, Nipro Premier, and OneTouchUltra 2.
conclusionsThis paper describes a simple, laboratory-based method to test glucometers across a wide range of hematocrit values and glucose concentrations and contributes up-to-date testing data on currently available POC glucometers at ranges relevant to neonatal use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.